Key result
Prophylactic ureteral stent placement during hysterectomy for placenta accreta spectrum was associated with a lower risk of genitourinary injury (28% vs 51%; aOR 0.27, 95% CI 0.14-0.52).
Why the study?
To evaluate the association between prophylactic ureteral stent placement at the time of hysterectomy for placenta accreta spectrum and genitourinary injury.
Does prophylactic ureteral stent placement reduce genitourinary injury in patients undergoing hysterectomy for placenta accreta spectrum?
Cohort (n=236)
Yes
Does prophylactic ureteral stent placement reduce genitourinary injury in patients undergoing hysterectomy for placenta accreta spectrum?
Odds Ratio: 0.27 (95% CI 0.14–0.52)
Absolute Event Rate: 28% vs 51%
Prophylactic ureteral stent placement during hysterectomy for placenta accreta spectrum is associated with a significantly decreased risk of genitourinary injury.
OBJECTIVE: To evaluate the association between prophylactic ureteral stent placement at the time of hysterectomy for placenta accreta spectrum and genitourinary injury. METHODS: We conducted a retrospective cohort study of patients with placenta accreta spectrum who underwent hysterectomy at two referral centers from 2001 to 2021. The exposure was prophylactic ureteral stent placement. The primary outcome, genitourinary injury, was a composite of bladder injury, ureteral injury, or vesicovaginal fistula. Secondary outcomes included components of the primary outcome. We evaluated differences between groups using χ 2 and t test. To evaluate differences in the primary outcome, we reported odds ratios (ORs) and adjusted odds ratios (aORs) using multivariable logistic regression analyses to control for potential confounding variables. We used a Cochran-Armitage χ 2 trend test to evaluate difference in stent use and injury over time. RESULTS: In total, 236 patients were included. Prophylactic ureteral stents were used in 156 surgeries (66%). Overall, genitourinary injury occurred less frequently in the stent group compared with the no stent group (28% vs 51%, OR 0.37, 95% CI 0.21-0.65). This association persisted after controlling for urgency of delivery, three or more prior cesarean deliveries, and whether a gynecologic oncologist was present (aOR 0.27, 95% CI 0.14-0.52). Unintentional bladder injury occurred less frequently in the stent group compared with the no stent group (13% vs 25%, P =.018), as did ureteral injury (2% vs 9%, P =.019). CONCLUSION: Prophylactic ureteral stent placement was associated with a decreased risk of genitourinary injury during hysterectomy for placenta accreta spectrum.
No takes yet. Share an insight, caveat, or question.
Scaglione et al. (2022) conducted a cohort in Placenta accreta spectrum (n=236). Prophylactic ureteral stent placement vs. No stent was evaluated on Genitourinary injury (composite of bladder injury, ureteral injury, or vesicovaginal fistula) (aOR 0.27, 95% CI 0.14-0.52). Prophylactic ureteral stent placement during hysterectomy for placenta accreta spectrum was associated with a lower risk of genitourinary injury (28% vs 51%; aOR 0.27, 95% CI 0.14-0.52).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: